Q3 Earnings Estimate for Zenas BioPharma Issued By Wedbush

Key Points

• Wedbush downgraded Zenas BioPharma's Q3 2025 earnings estimate significantly from $1.91 to ($0.27) per share, while maintaining an "Outperform" rating and a target price of $40.00.
• Insider buying activity is notable, with Leon O. Moulder, Jr. and Hongbo Lu purchasing 36,928 and 263,160 shares, respectively, indicating a confidence in the company's potential despite its challenges.
• Recent consensus ratings on Zenas BioPharma include three "Buy" ratings and one "Sell" rating, with an average target price set at $38.33.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Research analysts at Wedbush dropped their Q3 2025 earnings per share estimates for shares of Zenas BioPharma in a report issued on Thursday, October 9th. Wedbush analyst M. Fan now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of $1.91. Wedbush currently has a "Outperform" rating and a $40.00 target price on the stock. Wedbush also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($1.54) EPS, Q2 2026 earnings at ($1.55) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.42) EPS, FY2026 earnings at ($5.90) EPS, FY2027 earnings at ($4.66) EPS, FY2028 earnings at ($4.72) EPS and FY2029 earnings at ($3.23) EPS.

Several other research analysts have also recently weighed in on ZBIO. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Zenas BioPharma in a research report on Thursday. Wall Street Zen lowered shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Friday, September 26th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zenas BioPharma in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.33.

Zenas BioPharma Trading Down 4.2%

ZBIO stock opened at $26.59 on Monday. Zenas BioPharma has a 12-month low of $5.83 and a 12-month high of $29.73. The stock has a market cap of $1.12 billion and a price-to-earnings ratio of -7.49. The business's 50-day moving average is $18.86 and its 200 day moving average is $13.43.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Insider Buying and Selling

In other Zenas BioPharma news, insider Leon O. Moulder, Jr. bought 36,928 shares of Zenas BioPharma stock in a transaction dated Tuesday, October 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $769,948.80. Following the completion of the acquisition, the insider owned 36,928 shares of the company's stock, valued at approximately $769,948.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hongbo Lu bought 263,160 shares of Zenas BioPharma stock in a transaction dated Tuesday, October 7th. The stock was acquired at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the completion of the acquisition, the director directly owned 321,983 shares of the company's stock, valued at approximately $6,117,677. The trade was a 447.38% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 616,307 shares of company stock worth $11,778,150. Corporate insiders own 16.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC increased its holdings in Zenas BioPharma by 13.9% in the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock valued at $128,000 after buying an additional 1,607 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares in the last quarter. Bank of America Corp DE increased its holdings in Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock valued at $136,000 after buying an additional 3,412 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Zenas BioPharma in the first quarter valued at about $49,000. Finally, Rhumbline Advisers increased its stake in shares of Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock worth $191,000 after purchasing an additional 8,207 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.